kneat.com Competitors

kneat.com (CVE:KSI) and Burcon NutraScience (TSE:BU) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, earnings, institutional ownership, dividends, valuation and risk.

Valuation and Earnings

This table compares kneat.com and Burcon NutraScience's top-line revenue, earnings per share (EPS) and valuation.

Burcon NutraScience has lower revenue, but higher earnings than kneat.com. kneat.com is trading at a lower price-to-earnings ratio than Burcon NutraScience, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares kneat.com and Burcon NutraScience's net margins, return on equity and return on assets.

Analyst Recommendations

This is a summary of recent recommendations for kneat.com and Burcon NutraScience, as provided by MarketBeat.com.

kneat.com currently has a consensus target price of C$2.75, suggesting a potential downside of 9.24%. Burcon NutraScience has a consensus target price of C$5.00, suggesting a potential upside of 24.38%. Given Burcon NutraScience's higher probable upside, analysts clearly believe Burcon NutraScience is more favorable than kneat.com.

Summary

Burcon NutraScience beats kneat.com on 5 of the 6 factors compared between the two stocks.

Aptose Biosciences (TSE:APS) and kneat.com (CVE:KSI) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their institutional ownership, dividends, analyst recommendations, profitability, risk, valuation and earnings.

Valuation and Earnings

This table compares Aptose Biosciences and kneat.com's gross revenue, earnings per share and valuation.

Aptose Biosciences has higher earnings, but lower revenue than kneat.com. kneat.com is trading at a lower price-to-earnings ratio than Aptose Biosciences, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of current ratings and target prices for Aptose Biosciences and kneat.com, as provided by MarketBeat.com.

Aptose Biosciences presently has a consensus price target of C$12.00, indicating a potential upside of 151.57%. kneat.com has a consensus price target of C$2.75, indicating a potential downside of 9.24%. Given Aptose Biosciences' higher possible upside, equities research analysts plainly believe Aptose Biosciences is more favorable than kneat.com.

Profitability

This table compares Aptose Biosciences and kneat.com's net margins, return on equity and return on assets.

Summary

Aptose Biosciences beats kneat.com on 3 of the 5 factors compared between the two stocks.

kneat.com (CVE:KSI) and Nuvo Pharmaceuticals Inc. (NRI.TO) (TSE:NRI) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, institutional ownership, valuation, profitability and risk.

Profitability

This table compares kneat.com and Nuvo Pharmaceuticals Inc. (NRI.TO)'s net margins, return on equity and return on assets.

Analyst Ratings

This is a summary of recent recommendations and price targets for kneat.com and Nuvo Pharmaceuticals Inc. (NRI.TO), as provided by MarketBeat.

kneat.com presently has a consensus price target of C$2.75, indicating a potential downside of 9.24%. Given kneat.com's higher possible upside, analysts plainly believe kneat.com is more favorable than Nuvo Pharmaceuticals Inc. (NRI.TO).

Valuation & Earnings

This table compares kneat.com and Nuvo Pharmaceuticals Inc. (NRI.TO)'s gross revenue, earnings per share and valuation.

kneat.com has higher earnings, but lower revenue than Nuvo Pharmaceuticals Inc. (NRI.TO). kneat.com is trading at a lower price-to-earnings ratio than Nuvo Pharmaceuticals Inc. (NRI.TO), indicating that it is currently the more affordable of the two stocks.

Summary

kneat.com beats Nuvo Pharmaceuticals Inc. (NRI.TO) on 4 of the 6 factors compared between the two stocks.

Canopy Rivers (TSE:RIV) and kneat.com (CVE:KSI) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, earnings, profitability, valuation and risk.

Profitability

This table compares Canopy Rivers and kneat.com's net margins, return on equity and return on assets.

Earnings & Valuation

This table compares Canopy Rivers and kneat.com's top-line revenue, earnings per share and valuation.

kneat.com has lower revenue, but higher earnings than Canopy Rivers. kneat.com is trading at a lower price-to-earnings ratio than Canopy Rivers, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent ratings and price targets for Canopy Rivers and kneat.com, as reported by MarketBeat.

Canopy Rivers currently has a consensus target price of C$4.00, suggesting a potential upside of 40.85%. kneat.com has a consensus target price of C$2.75, suggesting a potential downside of 9.24%. Given Canopy Rivers' higher possible upside, equities research analysts plainly believe Canopy Rivers is more favorable than kneat.com.

Summary

kneat.com beats Canopy Rivers on 5 of the 8 factors compared between the two stocks.

kneat.com (CVE:KSI) and BELLUS Health (TSE:BLU) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, earnings, profitability, dividends, risk and institutional ownership.

Valuation and Earnings

This table compares kneat.com and BELLUS Health's top-line revenue, earnings per share (EPS) and valuation.

kneat.com has higher revenue and earnings than BELLUS Health. kneat.com is trading at a lower price-to-earnings ratio than BELLUS Health, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares kneat.com and BELLUS Health's net margins, return on equity and return on assets.

Analyst Ratings

This is a breakdown of recent ratings and target prices for kneat.com and BELLUS Health, as reported by MarketBeat.com.

kneat.com currently has a consensus price target of C$2.75, suggesting a potential downside of 9.24%. Given kneat.com's stronger consensus rating and higher probable upside, research analysts plainly believe kneat.com is more favorable than BELLUS Health.

Summary

kneat.com beats BELLUS Health on 5 of the 8 factors compared between the two stocks.

Theratechnologies (TSE:TH) and kneat.com (CVE:KSI) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, earnings, risk, analyst recommendations, institutional ownership, dividends and valuation.

Profitability

This table compares Theratechnologies and kneat.com's net margins, return on equity and return on assets.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Theratechnologies and kneat.com, as reported by MarketBeat.com.

Theratechnologies presently has a consensus target price of C$3.75, suggesting a potential downside of 5.06%. kneat.com has a consensus target price of C$2.75, suggesting a potential downside of 9.24%. Given Theratechnologies' higher possible upside, research analysts clearly believe Theratechnologies is more favorable than kneat.com.

Valuation and Earnings

This table compares Theratechnologies and kneat.com's revenue, earnings per share (EPS) and valuation.

kneat.com has lower revenue, but higher earnings than Theratechnologies. kneat.com is trading at a lower price-to-earnings ratio than Theratechnologies, indicating that it is currently the more affordable of the two stocks.

Summary

kneat.com beats Theratechnologies on 5 of the 8 factors compared between the two stocks.